测试版
试验雷达 AI
临床试验 NCT07493746 针对髋关节发育不良目前尚未招募。请查看临床试验雷达卡片视图和 AI 发现工具了解所有详情,或在此提出任何问题。
一个试验符合筛选条件
卡片视图

Hip Arthroscopy Versus Conservative Treatment for Borderline Hip Dysplasia 248 运动

尚未招募
临床试验详情主要以英语提供。然而,试验雷达 AI可以提供帮助!只需点击“试验详解”即可查看和讨论您选择的语言的试验信息。
临床试验NCT07493746是一项针对髋关节发育不良干预性研究试验,当前状态为尚未招募试验尚未开始,计划于2026年6月1日开始,预计招募248名患者。该研究由ChunBao Li主导,计划于2029年6月30日完成。试验数据来源于ClinicalTrials.gov,最后更新时间为2026年3月25日
简要概括
The goal of this clinical trial is to compare the efficacy of hip arthroscopy versus individualized conservative treatment in patients with borderline developmental dysplasia of the hip (BDDH), defined by a lateral center-edge angle (LCEA) of 18-25°. The main question it aims to answer is: which treatment approach, surgical or conservative, provides superior pain relief, functional recovery, and quality of life impro...显示更多
详细描述
This multicenter, prospective, randomized controlled trial aims to compare the efficacy of hip arthroscopy versus individualized conservative treatment in patients with borderline developmental dysplasia of the hip (BDDH). BDDH, defined by a lateral center-edge angle (LCEA) of 18-25°, represents a distinct condition between normal hips and developmental dysplasia of the hip, and its optimal management remains controv...显示更多
官方标题

Arthroscopic Hip Surgery Versus Individualized Conservative Treatment for Borderline Hip Dysplasia: A Multicenter Prospective Randomized Controlled Trial

疾病
髋关节发育不良
其他研究标识符
  • 2026KY001-HS001
NCT编号
实际开始日期
2026-06-01
最近更新发布
2026-03-25
预计完成日期
2029-06-30
计划入组人数
248
研究类型
干预性研究
试验分期 (阶段)
不适用
试验状态
尚未招募
关键词
Borderline hip dysplasia; Arthroscopy; Conservative treatment
主要目的
治疗方法
分配方式
随机
干预模型
平行
盲法
单盲
试验组/干预措施
参与者组/试验组干预措施/治疗方法
实验性Hip arthroscopy
髋关节镜检查
The surgical group will undergo standardized hip arthroscopy with capsular management, acetabular rim limited trimming, labral repair, and Cam deformity correction when indicated.
阳性对照Individualized conservative treatment
Individualized conservative treatment
The conservative treatment protocol includes patient education, NSAIDs for 2-4 weeks, chondroprotective supplementation for 8 weeks, and supervised progressive exercise training for 3 months.
主要终点
结果指标度量标准描述时间框架
The modified Harris Hip Score
The primary outcome was the modified Harris Hip Score (mHHS), assessed at pre-intervention, and at 12 and 24 months post-randomization. It is a clinician-reported instrument designed to evaluate hip function, commonly used to assess functional recovery before and after conservative treatment or hip arthroscopy. The scale encompasses domains such as pain, function, joint range of motion, and deformity, providing a total score ranging from 0 to 100, with higher scores indicating better hip function (typically, 90-100 points represent excellent, 80-89 good, 70-79 fair, and \<70 poor). The instrument has been validated in a relevant population for this trial, with a minimum clinically important difference of 9 points and a patient-acceptable symptom state threshold of 78 points.
Pre-intervention, and at 12 and 24 months post-randomization
次要终点
结果指标度量标准描述时间框架
Visual Analogue Scale
The pain Visual Analogue Scale (VAS) score is a patient-reported instrument designed to quantify pain intensity. It uses a 100-mm line anchored by "no pain" and "worst imaginable pain," with a total score ranging from 0 to 100, where higher scores indicate more severe pain. This instrument has been validated in a relevant population for this trial.
Pre-intervention, and at 12 and 24 months post-randomization
International Hip Outcome Tool-12
The iHOT-12 (international Hip Outcome Tool-12) score is a patient-reported instrument designed to assess hip-related quality of life. Derived from the full iHOT-33 scale, this 12-item instrument covers domains such as symptoms, functional limitations, sports and recreational activities, and work-related concerns. It provides a total score ranging from 0 to 100, with higher scores indicating better hip function and quality of life.
Pre-intervention, and at 12 and 24 months post-randomization
General health: Short Form questionnaire-12 items
The 12-Item Short Form Survey (SF-12) is a validated and widely used health-related quality of life measure, commonly applied to assess hip conditions and treatment outcomes. The SF-12 generates the physical and mental component summary scores originally derived from the 36-Item Short Form Survey (SF-36) with considerable accuracy, while significantly reducing respondent burden. This 12-item scale comprises two dimensions: positive mental state and psychological distress symptoms. Scores from all items are summed to obtain a total score, with higher scores indicating more severe psychological distress.
Pre-intervention, and at 12 and 24 months post-randomization
Patient satisfaction
Patient satisfaction was measured using questions that our team had used in previous trials involving patients undergoing hip arthroscopy for BDDH. During follow-up, we assessed satisfaction in all participants by asking: "Overall, how satisfied are you with the treatment you received?" Responses were rated on a scale from 1 to 10, where 1 indicated dissatisfied and 10 indicated very satisfied.
12 and 24 months post-randomization
Clinical assessment
Clinical assessment performed at baseline and follow up visits consisted of range of passive hip movement, measured using a goniometer, and recording whether a participant experienced pain on each movement. Impingement tests determined whether a participant experienced pain on hip flexion, adduction, and internal rotation (FADIR) or flexion, abduction, and external rotation (FABER).
Pre-intervention, and at 12 and 24 months post-randomization
Adverse events
We recorded the number and type of adverse events up to 24 months. Any adverse events were recorded on the appropriate case report forms and returned to the clinical trial unit, where the chief investigator determined causality and expectedness. Serious adverse events deemed unexpected and related to the trial were reported to the Research Ethics Committee within 10 days.
post-randomization
参与助手
资格标准

适龄参与研究
成人
最低年龄要求
18 Years
适龄性别
全部
  1. Age 18-42 years (studies have reported age ≥42 years as a risk factor for hip arthroscopy in BDDH: HR=11.6, 95% CI: 2.5-53.9), either sex;
  2. Symptoms (anterior-lateral groin, lateral, or posterolateral hip pain or discomfort), physical examination findings (limp, clicking, locking, and limited range of motion), and imaging findings consistent with BDDH diagnosis (standing anteroposterior pelvic radiograph with Wiberg lateral center-edge angle \[LCEA\] 18-25°);
  3. Surgeon's assessment that the patient with BDDH will benefit from hip arthroscopy or conservative treatment;
  4. Full understanding of trial benefits and risks, willingness to participate in the intervention and complete follow-up, and signed informed consent.

  1. Standing anteroposterior pelvic radiograph showing Tönnis grade ≥2 and/or joint space <2 mm;
  2. Standing anteroposterior pelvic radiograph showing FEAR index >5°;
  3. Positive physical examination for joint instability: anterior apprehension test (HEER test), abduction-extension-external rotation test in lateral decubitus position (AB-HEER test), or prone external rotation test;
  4. History of high-energy hip trauma, previous ipsilateral or contralateral hip surgery, avascular necrosis of the femoral head, slipped capital femoral epiphysis, Perthes disease, severe osteoporosis, tumor, acetabular stress fracture, or hypertrophic or inflammatory hip disease;
  5. Concomitant consciousness disorder, psychiatric illness, or neuromuscular dysfunction affecting lower limb function;
  6. Contraindications to hip arthroscopy (such as systemic or local infection).
ChunBao Li logoChunBao Li
研究责任方
ChunBao Li, 申办者-研究者, Director of the Department of Sports Medicine, Chinese PLA General Hospital
没有联系数据。